We are in initial stages to look at collaboration in biotech and clinical research.

We are not in any spree of acquisition right now.

India is an important part in our development program, and we are looking at collaborations with Indian companies in clinical programs and biotechnology.

Less than ten per cent of cancer research funding goes to early detection. Our emphasis is on collaboration across technologies and institutions. We have assembled some of the world's leading researchers, including Dr. Brad Nelson from the BC Cancer Agency, to attack early detection in a new collaborative approach.

ASN combines the extensive supplier research assessment and negotiation capabilities of A. T. Kearney with the collaboration, content exchange, and sourcing enablement of UGS technologies and the far reaching business experience and recognized quality services of TCS to offer low-cost country sourcing as a packaged solution.

ASN combines the extensive supplier research assessment and negotiation capabilities of A.T. Kearney with the collaboration, content exchange, and sourcing enablement of UGS technologies and the far reaching business experience and recognized quality services of TCS to offer low-cost country sourcing as a packaged solution.